Featured Article

With a novel pharmacogenomic platform, Leapfrog Bio is screening clinically actionable molecules to target major solid tumor markets in a condensed timeline requiring far fewer resources.

Precision Oncology Today

Magazine

Applying Precision Technology to Tackle Climate-Driven Infectious Diseases

The devastating impact that infectious diseases can have on the global population was well demonstrated by the COVID-19 pandemic. Fortunately, pandemics remain unusual occurrences, but research suggests that factors such as climate change may be increasing the risk of such events occurring in the future. Integrative projects that simultaneously tackle infectious disease risks, climate change, and other environmental issues could help solve a complicated global problem.
Blood Testing

Minimal Disease, Maximum Benefit

As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Antibodies Background

Immunogenomics is on the Way Up

Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.

Trending on Inside Precision Medicine

Blood Testing

New Blood Test Predicts Risk for COPD and Severe Respiratory Diseases

A team of scientists supported by the National Institutes of Health (NIH) has developed a promising blood test that could predict the risk of developing severe respiratory diseases, such as chronic obstructive pulmonary disease (COPD).
Pills Loading

Burn Rubber: Superluminal Medicines Gets $120M to Take GPCR Drugs to Clinic

The funds will move Superluminal's lead program from animal testing to the clinic, expand the pipeline, and advance their computational and data-heavy platform.
Melanoma Tissue

Age-Related Changes in Fibroblasts Drive Treatment-Resistant Melanoma in Males

Research in human cells and in mice by scientists at the Johns Hopkins Kimmel Cancer Center suggests that age-related changes in fibroblasts contribute to the development of aggressive, treatment-resistant melanoma in males.

Daily News

Related Content

Inside Precision Medicine